Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

A Crystal Ball For Drug Launch Success? Try Consensus Estimates

27 Mar 2012

• By Lisa LaMotta

Related Content

Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012

16 Feb 2012

Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations

26 Sep 2011

Related Companies

BioMarin Pharmaceutical Inc.

NPS Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Vertex Pharmaceuticals Incorporated

Biogen, Inc.

InterMune, Inc.

Corcept Therapeutics Incorporated

Incyte Corporation

Ionis Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Alexion Pharmaceuticals Inc.

Roche Holding AG

Genentech, Inc.

Additional Topics

Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.